Key result
For NOACs, APTT and PT gauge bleeding risk while soluble fibrin monomer complex assesses ischemic risk.
Why the study?
How can bleeding and ischemia risks be evaluated in patients receiving novel oral anticoagulants?
How can bleeding and ischemia risks be evaluated in patients receiving novel oral anticoagulants?
Thrombosis markers like FMC are useful for evaluating ischemia risk in NOAC therapy, but absolute markers for bleeding risk are still lacking and require further development.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ieko et al. (2013) conducted a review in Cardiogenic cerebral embolism / Anticoagulant therapy. Novel oral anticoagulants (NOACs) was evaluated. In patients receiving novel oral anticoagulants, APTT and PT are useful for evaluating bleeding risk despite reagent variability, while soluble fibrin monomer complex is highly effective for assessing ischemic risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: